{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:43:11Z","timestamp":1790239391141,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,8,7]],"date-time":"2014-08-07T00:00:00Z","timestamp":1407369600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s00280-014-2554-1","type":"journal-article","created":{"date-parts":[[2014,8,6]],"date-time":"2014-08-06T04:57:27Z","timestamp":1407301047000},"page":"729-737","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies"],"prefix":"10.1007","volume":"74","author":[{"given":"Jean-Pascal","family":"Machiels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Staddon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Herremans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Keung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apexa","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Phelps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nushmia Z.","family":"Khokhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Knoblauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trilok V.","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Dirix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,7]]},"reference":[{"key":"2554_CR1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0959-8049(00)00357-9","volume":"37","author":"E Erba","year":"2001","unstructured":"Erba E, Bergamaschi D, Bassano L, Damia G, Ronzoni S, Faircloth GT, D\u2019Incalci M (2001) Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 37:97\u2013105","journal-title":"Eur J Cancer"},{"key":"2554_CR2","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/91008","volume":"7","author":"Y Takebayashi","year":"2001","unstructured":"Takebayashi Y, Pourquier P, Zimonjic DB, Nakayama K, Emmert S, Ueda T, Urasaki Y, Kanzaki A, Akiyama SI, Popescu N, Kraemer KH, Pommier Y (2001) Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 7:961\u2013966","journal-title":"Nat Med"},{"key":"2554_CR3","unstructured":"EMA Yondelis (2012) EPAR summary for the public. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/000773\/WC500045833.pdf . Accessed 12 Aug 2013"},{"key":"2554_CR4","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2165\/00003088-200746100-00005","volume":"46","author":"JJ Perez-Ruixo","year":"2007","unstructured":"Perez-Ruixo JJ, Zannikos P, Hirankarn S, Stuyckens K, Ludwig EA, Soto-Matos A, Lopez-Lazaro L, Owen JS (2007) Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients. Clin Pharmacokinet 46:867\u2013884","journal-title":"Clin Pharmacokinet"},{"key":"2554_CR5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2174\/157488409787236047","volume":"1","author":"JH Beumer","year":"2009","unstructured":"Beumer JH, Lopez-Lazaro L, Schellens JH, Beijnen JH, van Tellingen O (2009) Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743). Curr Clin Pharmacol 1:38\u201342","journal-title":"Curr Clin Pharmacol"},{"key":"2554_CR6","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1634\/theoncologist.2009-0104","volume":"14","author":"MK Chuk","year":"2009","unstructured":"Chuk MK, Balis FM, Fox E (2009) Trabectedin. Oncologist 14:794\u2013799","journal-title":"Oncologist"},{"key":"2554_CR7","unstructured":"Guidance for Industry (2012) Drug interaction studies\u2014Study design, data analysis, implications for dosing, and labeling recommendations. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm292362.pdf . Accessed 10 Sept 2013"},{"key":"2554_CR8","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1067\/mcp.2001.117283","volume":"70","author":"T Kerbusch","year":"2001","unstructured":"Kerbusch T, Jansen RL, Mathot RA, Huitema AD, Jansen M, van Rijswijk RE, Beijnen JH (2001) Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin. Clin Pharmacol Ther 70:132\u2013141","journal-title":"Clin Pharmacol Ther"},{"key":"2554_CR9","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00280-012-2038-0","volume":"71","author":"U Lassen","year":"2013","unstructured":"Lassen U, Miller WH, Hotte S, Evans TR, Kollmansberger C, Adamson D, Nielsen DL, Spicer J, Chen E, Meyer T, Brown K, Rafi R, Sawyer MB (2013) Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours. Cancer Chemother Pharmacol 71:543\u2013549","journal-title":"Cancer Chemother Pharmacol"},{"key":"2554_CR10","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1158\/1078-0432.CCR-10-0062","volume":"16","author":"Q Chu","year":"2010","unstructured":"Chu Q, Mita A, Forouzesh B, Tolcher AW, Schwartz G, Nieto A, Soto-Matos A, Alfaro V, Lebedinsky C, Rowinsky EK (2010) Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2\u00a0weeks in patients with advanced solid tumors. Clin Cancer Res 16:2656\u20132665","journal-title":"Clin Cancer Res"},{"key":"2554_CR11","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1158\/1078-0432.CCR-08-2889","volume":"15","author":"B Forouzesh","year":"2009","unstructured":"Forouzesh B, Hidalgo M, Chu Q, Mita A, Mita M, Schwartz G, Jimeno J, Gomez J, Alfaro V, Lebedinsky C, Zintl P, Rowinsky EK (2009) Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies. Clin Cancer Res 15:3591\u20133599","journal-title":"Clin Cancer Res"},{"key":"2554_CR12","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/annonc\/mdn363","volume":"19","author":"M Mehren von","year":"2008","unstructured":"von Mehren M, Schilder RJ, Cheng JD, Temmer E, Cardoso TM, Renshaw FG, Bayever E, Zannikos P, Yuan Z, Cohen RB (2008) A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Ann Oncol 19:1802\u20131809","journal-title":"Ann Oncol"},{"key":"2554_CR13","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1517\/14740338.2013.829037","volume":"12","author":"J Martin-Liberal","year":"2013","unstructured":"Martin-Liberal J, Judson I (2013) Safety evaluation of trabectedin in treatment of soft-tissue sarcomas. Expert Opin Drug Saf 12:905\u2013911","journal-title":"Expert Opin Drug Saf"},{"key":"2554_CR14","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1007\/s10637-013-9942-y","volume":"31","author":"C Sessa","year":"2013","unstructured":"Sessa C, Del Conte G, Christinat A, Cresta S, Perotti A, Gallerani E, Lardelli P, Kahatt C, Alfaro V, Iglesias JL, Fernandez-Teruel C, Gianni L (2013) Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors. Invest New Drugs 31:1236\u20131243","journal-title":"Invest New Drugs"},{"key":"2554_CR15","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00280-011-1697-6","volume":"69","author":"R Thertulien","year":"2012","unstructured":"Thertulien R, Manikhas GM, Dirix LY, Vermorken JB, Park K, Jain MM, Jiao JJ, Natarajan J, Parekh T, Zannikos P, Staddon AP (2012) Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies. Cancer Chemother Pharmacol 69:341\u2013350","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2554-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2554-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2554-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:11:40Z","timestamp":1559038300000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2554-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,7]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["2554"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2554-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,7]]}}}